Author Correction: Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Guardado en:
Autores principales: | Fanny Lebreton, Vanessa Lavallard, Kevin Bellofatto, Romain Bonnet, Charles H. Wassmer, Lisa Perez, Vakhtang Kalandadze, Antonia Follenzi, Michel Boulvain, Julie Kerr-Conte, David J. Goodman, Domenico Bosco, Thierry Berney, Ekaterine Berishvili |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea4a34ebd09e433b8c7a212425854b95 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes
por: Fanny Lebreton, et al.
Publicado: (2019) -
Development of islet organoids from human induced pluripotent stem cells in a cross-linked collagen scaffold
por: Shruti Sandilya, et al.
Publicado: (2021) -
Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors.
por: Clare L Kirkpatrick, et al.
Publicado: (2010) -
Intraperitoneal administration of human "Neo-Islets", 3-D organoids of mesenchymal stromal and pancreatic islet cells, normalizes blood glucose levels in streptozotocin-diabetic NOD/SCID mice: Significance for clinical trials.
por: Christof Westenfelder, et al.
Publicado: (2021) -
Intraperitoneal administration of human “Neo-Islets”, 3-D organoids of mesenchymal stromal and pancreatic islet cells, normalizes blood glucose levels in streptozotocin-diabetic NOD/SCID mice: Significance for clinical trials
por: Christof Westenfelder, et al.
Publicado: (2021)